Ads
related to: breathing problems with multiple myeloma patients- Phase 3 Trials
See Study Results
From the Latest Trial
- Treatment Schedule
Learn How This Treatment Is Given
See the Infusion Schedule
- Safety Information
Read Safety Information
for Patients and Caregivers
- Patient Support Program
Eligible Patients May Qualify
for Financial Assistance
- Phase 3 Trials
Search results
Results From The WOW.Com Content Network
Central neurogenic hyperventilation (CNH) is an abnormal pattern of breathing characterized by deep and rapid breaths at a rate of at least 25 breaths per minute. Increasing irregularity of this respiratory rate generally is a sign that the patient will enter into coma.
Between 40 and 80 percent of patients with cancer pain experience neuropathic pain. [1]Brain. Brain tissue itself contains no nociceptors; brain tumors cause pain by pressing on blood vessels or the membrane that encapsulates the brain (the meninges), or indirectly by causing a build-up of fluid that may compress pain-sensitive tissue.
Multiple myeloma is the second-most prevalent blood cancer (10%) after non-Hodgkin's lymphoma. [154] It represents about 1.8% of all new cancers and 2.1% of all cancer deaths. [7] Multiple myeloma affects slightly more men than women.
The patient's own description is the best measure of pain; they will usually be asked to estimate intensity on a scale of 0–10 (with 0 being no pain and 10 being the worst pain they have ever felt). [10] Some patients, however, may be unable to give verbal feedback about their pain.
5) Proteasome inhibitors, namely bortezomib, are used in the treatment of multiple myeloma and certain types of lymphoma. Bortezomib increases the production of sphingosine-1 phosphate , tumor necrosis factor α , and interleukin-1β , which ultimately leads to the development of neuropathic pain.
Treatment of patients with this POEMS syndrome variant who have evidence of bone lesions and/or myeloma proteins are the same as those for POEMS syndrome patients. In the absence of these features, treatment with rituximab , a monoclonal antibody preparation directed against B cells bearing the CD20 antigen, or siltuximab , a monoclonal ...
Ad
related to: breathing problems with multiple myeloma patients